Vantage logo

Myovant socks it to Orilissa

Two years after Abbvie’s disappointing launch of Orilissa Myovant hails the development of something much better.

Vantage logo

Horizon looks for a new growth driver

The company plans to make the most of its head start with the Graves’ disease project teprotumumab, which is forecast to become its biggest product.

Vantage logo

Myovant punished for success

A phase III win for the company’s uterine fibroids candidate fails to calm investor concerns about an expensive launch and a rival with deeper pockets.